O perating in austere environments and far-forward combat zones, special operations medics need a topical infection control wound treatment to prevent the onset of ''super infections'' on traumatic limb injuries, which also accelerates the healing process (Fig. 1) . The rationale is to minimize the chance of such infections as close as possible to the point of injury. It is important that the material is readily available, it is easy to use, and its temperature is stable. Both the US Air Force Surgeon General's Office for Medical Modernization (AF/SG5) and the Congressionally Directed Medical Research Program have recently asked medical researchers for practical, off-the-shelf solutions to meet the need for infection control against multidrug-resistant organisms (MDROs) including but not limited to methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Briefly, Expeditionary Casualty CareYfunded research is focused on optimizing existing and developing new casualty care tools and techniques, identifying and mitigating issues related to casualty care in expeditionary settings, and validation of best-fit technologies in casualty care mission(s).
US Air Force Pararescue Jumpers (PJs) are responsible for the movement of a casualty to a place of safety while providing initial essential stabilizing care at the point of injury to minimize loss of life and limb. Air Force Instruction 11-410, Section 10.3, on medical coverage, 1 lists the minimum equipment a PJ will carry. This demonstrates the limited ''weight and cube'' PJs have in their gear for improved equipment or supplies. Understanding this limitation, we proposed meeting the need for an easy-to-use, temperature-stable, topical wound treatment to prevent infections in traumatically injured and burned patients using MEDIHONEY (Derma Sciences, Inc., Toronto, Ontario M1S 3S4, Canada). This new product was cleared by the Food and Drug Administration in July 2007 2 to be used on diabetic ulcers, moderately to heavily exuding wounds such as first-degree and second-degree burns, as well as traumatic and surgical wounds. 3 In this initial report, we present data to support the in vitro efficacy of MEDIHONEY to mitigate ''super infections'' and therefore potentially speed up wound healing in our injured troops infected with MDROs. The immediate goal of this effort is to accelerate the transition of a novel approach for better traumatic wound healing therapy into the hands of first responders anywhere including but not limited to far-forward combat zones. The long-term impact of this study is to minimize the use of systemic antibiotics and reduce the onset of multidrug resistance in microorganisms through increasing the use of localized bactericidal therapy.
100% stock, ''active'' paste solution. Serial dilutions were prepared fresh from the latter, resulting in final concentrations from 20% to 0.5%, and were used immediately. Characterization of the bactericidal activity of MEDIHONEY was quantified using a microbroth dilution assay as described by Kwakman et al. 4 Briefly, for the minimum inhibitory concentration (MIC) testing, a sterile 96-well plate containing various concentrations of MEDIHONEY were inoculated with a standardized (1.0 Â 10 8 colony-forming units [CFUs]) bacterial suspension. After overnight incubation at 35-C, the MIC was determined by recording the lowest concentration of MEDIHONEY, which inhibited visible growth of bacterium as described by the Clinical and Laboratory Standard Institute guidelines. 5 The minimum bactericidal concentration (MBC) testing was performed to assess the ability of MEDIHONEY to kill bacterial isolates. It was determined from the lowest MIC concentration of honey showing no visible growth subcultured to blood agar plates. This provided an estimate of bacterial eradication, which is an accepted parameter in the evaluation of new antimicrobial agents as described in Clinical and Laboratory Standard Institute guidelines (M26-A). 6 The following two ''standard'' bacterial strains were selected for inoculation from the American Type Culture Collection (ATCC): (1) A. baumannii ATCC# BAA-1605Vmultidrug resistant (ABMDR), and (2) S. aureus ATCC# 43300Vresistant to oxacillin (MRSA). Identification and antimicrobial susceptibility profiles were confirmed using the automated Vitek 2 Compact, Etest, and the FilmArray (all systems from bioMeriux, Marcy I'Etoile, France). Furthermore, the multiple-drug resistance profile of these bacterial strains were ''fingerprinted'' using the Diversilab (bioMérieux, Inc., Durham, NC) and Agilent (Agilent Technologies, Inc., Life Sciences and Chemical Analysis, Wilmington, DE) bioanalyzer packages. Briefly, single-colony DNA signatures of these pathogens were generated from the initial cultures and were continuously monitored for genetic drifts or other changes.
RESULTS
The microbroth dilution method used here (Table 1) demonstrated the in vitro characterization of the antibacterial property of MEDIHONEY against MRSA and A. baumannii MDROs. Briefly, the MIC of honey against MRSA and A. baumannii was determined to be 3.5% and 8.5%, respectively. The MBC of MEDIHONEY was determined to be 9.5% for MRSA and 10.5% for A. baumannii. Together, these results provide evidence of MEDIHONEY's efficacy against these MDROs in vitro. Overnight culture results from all controls were negative. One drop (approximately 20 KL) of nondiluted ''supermarket brands'' (i.e., raw, processed, etc.) was inoculated into blood agar plates. After overnight incubation at 35-C, all the cultures showed diverse bacterial/fungal growth of 15 CFUs or greater. The MIC and MBC tests were not performed on these MDROs using supermarket brands because of positive mixed bacterial/fungal culture results from this source.
DISCUSSION
Naturally occurring honey was used by ancient civilizations for wound healing applications partly because of its antibacterial activity. 7, 8 With the advent of antibiotics, clinical application of honey was abandoned in modern Western medicine. However, the indiscriminant use of antibiotics has resulted in rapid and widespread emergence of antibioticresistant strains of bacteria. With the development of novel antibiotics lagging behind, 9 alternative antimicrobial strategies are urgently needed. The broad-spectrum antibacterial activity of honey is multifactorial in nature. 10 Hydrogen peroxide and high osmolarityVhoney consists of approximately 80% (wt./vol.) of sugarsVare the only well-characterized antibacterial factors in honey. 11 The hyperosmotic nature of honey prevents the growth of bacteria and yeast as it kills the organisms by dehydration. The low pH level (3.5Y4.5) 10 of the active medical grade Manuka honey used in MEDIHONEY inhibits bacterial colonization or infection that are usually accompanied by high pH values in wounds. Recently, high concentrations of the antibacterial compound methylglyoxal were found specifically in Manuka honey, derived from the Manuka tree (Leptospermum scoparium). 12 This suggests that honey derived from this pollen in this geographic region of the world makes it a more efficient bactericidal solution as compared with other types of medical grade honeys commercially available. Furthermore, the antimicrobial capability of this monofloral honey has been shown to prevent opportunistic fungal infections (candidiasis) in the treated areas.
9Y12
Our in vitro results support the use of MEDIHONEY as an effective antimicrobial therapy against MDROs. Even after several rounds of dilutions from the original stock, off-theshelf, initial concentration, MEDIHONEY maintained its bactericidal activity in vitro. When other commercially available honey sold as food was tested, mixed bacterial and fungal growth were observed. This substantiated the warning to avoid the use of supermarket brand honey for infants or wound The mechanism of MEDIHONEY as explained by the company is presented as a ''two-pronged'' approach (Fig. 2) . Briefly, the osmotic activity created by the gel patch keeps bodily fluids coming out of the affected area, keeping bacteria from further colonizing the wound. This also attracts macrophages to the area, which fight off opportunistic pathogens while contributing to wound debridement, which shortens recovery and healing time.
As the title of this report suggests, this is Part 1 of our two-part effort. The subsequent animal phase studies are focused on the efficacy of the MEDIHONEY in vivo using a novel murine model, which includes full-thickness burns, traumatic wound injuries, and infections with the MDROs in the same animal. Preliminary analyses of our in vivo data suggest that treatment with the MEDIHONEY allows for a faster recovery as evidenced by the wound healing progress and observed restoration of normal skin flora on our model (data not shown). Together, our results suggest that early (closest to the point of injury) treatment of traumatic wounds and burns with MEDIHONEY affords a faster wound healing process while minimizing the chances of developing a super infection by MDROs such as MRSA and A. baumannii. As we progress in this effort, we plan to assess the efficacy of this product against other highly infectious superbugs such as Clostridium difficile, and Pseudomonas aeruginosa among others, which were recently catalogued by the Centers for Disease Control and Prevention with threat levels as urgent. 13 As we continue to develop our in vivo phase (Part 2) of this effort, we understand the criticism of established murine models for wound healing.
14 Briefly, murine model of wound closure mechanism involves contraction, whereas in humans, this occurs via reepithelialization and granulation. Our preliminary results (data not shown) suggest that the wound healing progression in our optimized animal model seems to resemble the human wound healing process more closely. That is, although some contraction occurs, there seems to be granulation at wound bed on Day 21 of our study, especially in those animals treated with MEDIHONEY. Upon review of the literature, 15 there are numerous animal models for excisional wounds, full-thickness burns, and infections, using various rodents and other small mammals. However, there are no reports of a single animal model that combines all of these characteristics as seen in severe, traumatic combat wounds. We propose to further the use of this system to test and evaluate different products and devices in an effort to accelerate effective treatment modalities for use in far-forward, austere environments. 
